Andrade Chittaranjan
Department of Psychiatry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India; Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, India.
Corresponding Author: Chittaranjan Andrade, MD, Department of Psychiatry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India; Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, India (
J Clin Psychiatry. 2024 Dec 23;86(1):24f15717. doi: 10.4088/JCP.24f15717.
Up to 10% of women may use cannabis during pregnancy; this is of concern because constituents of cannabis cross the placental barrier and potentially influence neurodevelopment by acting on cannabinoid receptors in the developing fetal brain. In this context, a recent meta analysis of 13 observational studies found that gestational exposure to cannabis was associated with a small increase in the risk of autism spectrum disorder (ASD; relative risk [RR], 1.30) and with an even smaller increase in the risk of attention deficit/hyperactivity disorder (ADHD; RR, 1.13); the latter finding was probably supported by publication bias. In this meta-analysis, 4 studies provided information on ASD (pooled N = 178,565) and 10 on ADHD (pooled N = 203,783). In a large (n = 222,534) retrospectively ascertained cohort study published after the meta-analysis, cannabis use disorder (CUD) recorded before pregnancy, during pregnancy, and during pregnancy plus the year after delivery were associated with closely similar increased risks of ASD (RRs, 3.02-3.21). The risks were smaller in smokers (RRs, 1.74-1.87) than in nonsmokers (RRs, 4.55-4.83) but differed little between male (RRs, 3.01-3.06) and female (RRs, 2.71-2.85) offspring. Although the cohort study had many strengths, its limitations permitted only the conclusion that peri-pregnancy exposure to CUD is associated with a large increase in the risk of ASD in offspring; it remained possible that much of the risk was driven by genetic, environmental, or behavioral variables. The field is nascent; the total number of cannabis exposed pregnancies (with ASD and ADHD as the outcomes) in world literature is small. However, cannabis use during pregnancy is, at the very least, a clear marker for adverse neurodevelopmental outcomes, besides the adverse maternal, fetal, and neonatal outcomes identified in other studies. Healthcare providers who manage women who use cannabis during pregnancy need to be aware of these adverse outcomes.
高达10%的女性在孕期可能会使用大麻;这令人担忧,因为大麻的成分会穿过胎盘屏障,并可能通过作用于发育中胎儿大脑的大麻素受体来影响神经发育。在这种背景下,最近一项对13项观察性研究的荟萃分析发现,孕期接触大麻与自闭症谱系障碍(ASD;相对风险[RR],1.30)风险略有增加以及注意力缺陷/多动障碍(ADHD;RR,1.13)风险更小幅度增加有关;后一项发现可能受到发表偏倚的影响。在这项荟萃分析中,4项研究提供了关于ASD的信息(汇总样本量N = 178,565),10项研究提供了关于ADHD的信息(汇总样本量N = 203,783)。在荟萃分析之后发表的一项大型(n = 222,534)回顾性队列研究中,孕前、孕期以及孕期加产后一年记录的大麻使用障碍(CUD)与ASD风险增加密切相似(RRs,3.02 - 3.21)。吸烟者的风险(RRs,1.74 - 1.87)低于不吸烟者(RRs,4.55 - 4.83),但男性(RRs,3.01 - 3.06)和女性(RRs,2.71 - 2.85)后代之间差异不大。尽管该队列研究有许多优点,但其局限性仅允许得出这样的结论:围孕期接触CUD与后代患ASD的风险大幅增加有关;很大一部分风险仍有可能是由遗传、环境或行为变量驱动的。该领域尚处于起步阶段;世界文献中以ASD和ADHD为结局的大麻暴露孕期总数较少。然而,孕期使用大麻至少是不良神经发育结局的一个明确标志,此外还有其他研究中确定的不良母体、胎儿和新生儿结局。管理孕期使用大麻女性的医疗保健提供者需要了解这些不良结局。